Page 2 - J Nephrol Renovasc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from J nephrol renovasc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In J Nephrol Renovasc Today - Breaking & Trending Today

Boditech Med and SphingoTec close Market Development Agreement to Boost ...

Boditech Med and SphingoTec close Market Development Agreement to Boost . ....

South Korea , Kangwon Do , Republic Of Korea , Sphingotec Gmbh Ruxandra Lenz , J Nephrol Renovasc , Sphingotec Gmb , Sphingotec Gmbh , Eui Yul Choi , Duk Seung Naemail , News Network , Boditech Med Inc , Boditech Med , Kidney Injury , Diagnostic Approaches , Clin Biochem , Early Biomarker , Septic Acute Kidney Injury , Septic Shock , Kidney Int , Tec Gmbh , Med Inc , Sphingotec Gmbh Ruxandra Lenz Email ,

Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)

Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Czech Republic , United States , Isabella Zinck , Thomas Hungerbuehler , Van Praet , Jonathan Barratt , Samir Shah , Jamie Bennett , Julie Masow , Sloan Simpson , Phil Mcnamara , John Tsai , J Nephrol Renovasc , University Of Leicester , Head Of Global Drug Development , Novartis Institutes For Biomedical Research , Novartis Us External Communications , Exchange Commission , European Medicines Agency , Renal Medicine , Leicester General , Global Drug Development , Chief Medical Officer , Therapy Designation , Novartis Institutes , Biomedical Research ,

Novartis Pharma AG: Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)

Novartis Pharma AG: Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)
3-7
C3 glomerulopathy
Basel,
2
1 - Novartis today announced Phase II primary endpoint data showing investigational iptacopan (LNP023) - a first-in-class, oral, targeted factor B inhibitor - reduced protein in the urine (proteinuria), an increasingly recognized surrogate marker correlating with progression to kidney failure
2, and showed promise in stabilizing kidney function in patients with IgA nephropathy (IgAN)
1. The data were presented at the 58
th ERA-EDTA Congress held virtually from June 5-8, 2021.
In the Phase II study (NCT03373461), patients (n=112) with IgAN were randomized to placebo or different doses of iptacopan ....

Czech Republic , United States , Isabella Zinck , Thomas Hungerbuehler , Van Praet , Jonathan Barratt , Samir Shah , Jamie Bennett , Julie Masow , Sloan Simpson , Phil Mcnamara , John Tsai , J Nephrol Renovasc , University Of Leicester , Head Of Global Drug Development , Novartis Institutes For Biomedical Research , Novartis Us External Communications , Exchange Commission , European Medicines Agency , Renal Medicine , Leicester General , Global Drug Development , Chief Medical Officer , Therapy Designation , Novartis Institutes , Biomedical Research ,

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN) ....

Czech Republic , United Kingdom , United States , Isabella Zinck , Thomas Hungerbuehler , Van Praet , Jonathan Barratt , Samir Shah , Jamie Bennett , Julie Masow , Sloan Simpson , Phil Mcnamara , John Tsai , J Nephrol Renovasc , University Of Leicester , Head Of Global Drug Development , Novartis Institutes For Biomedical Research , Novartis Us External Communications , Exchange Commission , European Medicines Agency , Renal Medicine , Leicester General , Global Drug Development , Chief Medical Officer , Therapy Designation , Novartis Institutes ,

DGAP-News: Proenkephalin (penKid(R)) included in the ADQI consensus statements publication as functional kidney biomarker for the management of AKI patients

DGAP-News: Proen .
DGAP-News: Proenkephalin (penKid(R)) included in the ADQI consensus statements publication as functional kidney biomarker for the management of AKI patients
vom 16.12.2020, 10:00 Uhr
Bild: pixabay.com
DGAP-News: SphingoTec GmbH
/ Key word(s): Scientific publication/Statement
Proenkephalin (penKid(R)) included in the ADQI consensus statements publication as functional kidney biomarker for the management of AKI patients
16.12.2020 / 10:00
The issuer is solely responsible for the content of this announcement.
The latest consensus meeting of international experts in critical care and nephrology supports the use of novel biomarkers in the prevention and management of Acute Kidney Injury (AKI)
The consensus recommends using a combination of damage and functional biomarkers together with clinical information for routine practice ....

San Diego , United States , Andreas Bergmann , Sphingotec Gmbh , J Nephrol Renovasc , Sphingotec Gmb , Ruxandra Lenz , Peter Pickkers Radboud University , Disease Quality Initiative , Clin Chem Lab , Nexus Dx Inc , Distribution Services , Acute Kidney Injury , Acute Disease Quality Initiative , Care Unit , Peter Pickkers , Radboud University , Intj Nephrol Renovasc Dis , Acute Kidney Injury Biomarkers From , Consensus Statement , Critical Care Medicine , Early Biomarker , Septic Acute Kidney Injury , Septic Shock , Kidney Int Rep , New Biomarker ,